This thesis highlights the potential of HBC as a practical and scalable biomarker for improving the precision and effectiveness of TMS treatment for depression. While sleep disorders did not predict treatment outcomes, the use of HBC shows promise for enhancing personalized psychiatry and improving TMS response rates in the future. Large studies are needed to further validate HBC-TMS.
About the author(s)
Eva Dijkstra
Eva Dijkstra did her PhD at Brainclinics Foundation in collaboration with Maastricht University.
